
Merck KGaA has signed a worldwide licence agreement with Danish company Symphogen which could expand its portfolio of drugs targeting …

Merck KGaA has re-submitted Erbitux’s lung cancer licence extension to the EMA after its first application to the regulator was …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

